(1R,2R)-2-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxylic acid | 1807940-87-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1R,2R)-2-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxylic acid
• 英文别名: (1R,2R)-2-(1-methylpyrazol-4-yl)cyclopropane-1-carboxylic acid
• CAS: 1807940-87-9
• 化学式: C₈H₁₀N₂O₂
• 分子量: 166.18
• InChiKey: BLAROOKLCXZXMV-NKWVEPMBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1R,2R)-2-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxylic acid 、 ((6-((4bR,8aR)-2-amino-4b,7,7-trimethyl-4b,7,8,8a-tetrahydropyrano[3',4':4,5]pyrrolo[2,3-d]pyrimidin-9(5H)-yl)pyridin-2-yl)imino)dimethyl-λ6-sulfanone 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以29 %的产率得到(1R,2R)-N-((4bR,8aR)-9-(6-((dimethyl(oxo)-λ6-sulfaneylidene)amino)pyridin-2-yl)-4b,7,7-trimethyl-4b,5,7,8,8a,9-hexahydropyrano[3',4':4,5]pyrrolo[2,3-d]pyrimidin-2-yl)-2-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxamide
  参考文献：
  名称：

  TRICYCLIC COMPOUNDS

  摘要：

  The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases such as cancer.

  公开号：

  WO2024107393A1

文献信息

• NAPHTHYRIDINES AS INHIBITORS OF HPK1
  申请人：Genentech, Inc.

  公开号：US20180282328A1

  公开（公告）日：2018-10-04

  Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

  萘啶化合物及其作为HPK1抑制剂的用途被描述。这些化合物在治疗HPK1依赖性疾病和增强免疫反应方面很有用。还描述了抑制HPK1的方法、治疗HPK1依赖性疾病的方法、增强免疫反应的方法以及制备萘啶化合物的方法。
• [EN] BIARYL PYRAZOLES AS NRF2 REGULATORS<br/>[FR] BIARYL PYRAZOLES UTILISÉS COMME RÉGULATEURS DE NRF2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017060854A1

  公开（公告）日：2017-04-13

  The present invention relates to biaryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

  本发明涉及双芳基吡唑化合物、它们的制备方法、含有它们的药物组合物及其作为NRF2调节剂的应用。
• ISOQUINOLINES AS INHIBITORS OF HPK1
  申请人：Genentech, Inc.

  公开号：US20180282282A1

  公开（公告）日：2018-10-04

  Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

  描述了异喹啉化合物及其作为HPK1（造血激酶1）抑制剂的用途。这些化合物在治疗依赖于HPK1的疾病和增强免疫应答方面非常有用。还描述了抑制HPK1的方法、治疗依赖于HPK1的疾病的方法、增强免疫应答的方法，以及制备异喹啉化合物的方法。
• [EN] N-ARYL PYRAZOLES AS NRF2 REGULATORS<br/>[FR] N-ARYL PYRAZOLES EN TANT QUE RÉGULATEURS DE NRF2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018109642A1

  公开（公告）日：2018-06-21

  The present invention relates to N-aryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators. In particular, the compounds of this invention include a compound of Formula (I).

  本发明涉及N-芳基吡唑化合物，其制备方法，含有它们的药物组合物以及它们作为NRF2调节剂的用途。具体来说，本发明的化合物包括式（I）的化合物。
• [EN] DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1<br/>[FR] INHIBITEURS DE DIAMINOPYRIMIDINE CARBOXAMIDE DE HPK1
  申请人：MERCK SHARP & DOHME

  公开号：WO2022098809A1

  公开（公告）日：2022-05-12

  Compounds of the formula I: or the pharmaceutically acceptable salts thereof, are inhibitors of haematopoietic progenitor kinase 1 (HPK1) useful in the treatment of diseases or disorders associated with HPK1. Also disclosed herein are uses of these compounds in the potential treatment or prevention of an HPK1-associated disease or disorder. Also disclosed herein are compositions comprising one or more of the compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of an HPK1-associated disease or disorder.

  公式I的化合物或其药学上可接受的盐是血液造血祖细胞激酶1（HPK1）的抑制剂，可用于治疗与HPK1相关的疾病或紊乱。本文还披露了这些化合物在潜在的治疗或预防HPK1相关疾病或紊乱中的用途。本文还披露了包含一个或多个化合物的组合物。此外，本文还披露了这些组合物在潜在的预防或治疗HPK1相关疾病或紊乱中的用途。